Real-world insights on the management of iTTP with Caplacizumab
In this retrospective analysis of hospital chart review data relating to adult patients (≥18 years old) with iTTP who were hospitalized and treated with caplacizumab in 13 Belgian hospitals, the research group provides real-world data on the use of caplacizumab in Belgium. Dr. Ine Moors from UZ Gent explains.
With the educational support of:
